Ortho Preserve

Meniscus Implant for Knee Pain Treatment

Website: https://www.orthopreserve.com

Cover Block

PUBLIC

Field Value
Name OrthoPreserve
Tagline Meniscus Implant for Knee Pain Treatment
Headquarters Atlanta, Georgia
Founded 2021
Industry Medical Devices, Orthopedics
Technology Implantable meniscus replacement
Geography North America
Founding Team Jonathan Schwartz (Georgia Tech alum)
Funding Label NIH SBIR grant

Links

PUBLIC

Executive Summary

PUBLIC

OrthoPreserve is an Atlanta-based medical device startup developing a synthetic meniscus implant intended to treat knee pain in patients whose native meniscus tissue cannot be repaired, a clinical population that today is largely funneled toward partial meniscectomy and, eventually, total knee replacement. The company was spun out of Georgia Tech in 2021 by founder Jonathan Schwartz, whose graduate research formed the technical basis of the device [Georgia Tech, July 2024]; [Hypepotamus]. In early 2025, OrthoPreserve announced that the U.S. Food and Drug Administration granted the implant Breakthrough Device Designation and accepted it into the agency's Total Product Life Cycle Advisory Program (TAP), two regulatory signals that meaningfully de-risk the device's path to clinical study [PR Newswire]. Disclosed financing to date includes a National Institutes of Health SBIR grant, with Activation Capital named as an investor and the Advanced Technology Development Center (ATDC) at Georgia Tech named as the supporting accelerator [CB Insights]; [Southeast Venture Showcase]. Identified competitors in the meniscus segment include Active Implants and Orteq Ltd, alongside larger orthopedic incumbents such as Stryker that operate adjacent franchises in cartilage repair and knee reconstruction [CB Insights]. The company remains pre-clinical, so the next 12 to 18 months will be defined by the structure of the FDA-aligned clinical study, the size and lead of any priced equity round following the SBIR grant, and whether early surgeon advisors translate into named clinical investigators. For investors who track regenerative orthopedics, OrthoPreserve sits in a small group of meniscus replacement programs that have cleared an FDA Breakthrough hurdle, which is the principal reason it warrants a closer read at this stage.

Data Accuracy: GREEN -- Confirmed by PR Newswire, Georgia Tech News Center, CB Insights, and Hypepotamus.

Taxonomy Snapshot

Axis Value
Industry / Vertical Medical Devices, Orthopedics (meniscus replacement)
Technology Type Implantable synthetic meniscus
Geography North America (Atlanta, GA)
Founding Team Solo technical founder, university spinout
Funding NIH SBIR grant; Activation Capital named investor

Company Overview

PUBLIC

OrthoPreserve traces its origin to a graduate thesis at the Georgia Institute of Technology, where founder Jonathan Schwartz worked on an implantable meniscus replacement intended to preserve native knee biomechanics rather than simply remove damaged tissue [Georgia Tech, July 2024]; [Hypepotamus]. The company was incorporated in 2021 and is headquartered in Atlanta, where it has continued to develop the device through Georgia Tech's commercialization pathway and the Advanced Technology Development Center (ATDC), the state's primary technology incubator [Georgia Tech, July 2024]; [CB Insights].

The most consequential public milestone to date is the early-2025 announcement that the FDA granted the meniscus implant Breakthrough Device Designation and admitted the program into the Total Product Life Cycle Advisory Program (TAP) [PR Newswire]. Breakthrough Designation is reserved for devices that target serious or irreversibly debilitating conditions and offer advantages over existing approved alternatives, and TAP enrollment provides earlier and more structured access to FDA staff and to strategic stakeholders. Together, these designations are the clearest external validation OrthoPreserve has received that the agency views the unmet need as material.

Financing disclosures are limited. Public databases and the company's showcase profile reference an NIH SBIR grant and name Activation Capital as an investor, but the size, date, and structure of any equity round are not disclosed in the sources reviewed [CB Insights]; [Southeast Venture Showcase]. The company appears to operate as a small founder-led team rather than a fully built-out commercial organization, consistent with a pre-clinical medical device at this stage.

Data Accuracy: GREEN -- Confirmed by Georgia Tech News Center, PR Newswire, and CB Insights.

Product and Technology

MIXED

The core product is a synthetic meniscus implant intended to replace damaged meniscal tissue in the knee, positioned as an alternative to partial meniscectomy (which removes tissue and is associated with accelerated osteoarthritis) and as a delay or substitute for eventual total knee arthroplasty in younger patients [PR Newswire] [PUBLIC]; [Hypepotamus] [PUBLIC]. The company's public materials describe the device as designed to restore the meniscus's load-distribution function in the knee joint, which is the mechanical role most directly implicated in cartilage degeneration when the meniscus is lost [OrthoPreserve] [PUBLIC].

From a regulatory standpoint, the program is at the pre-clinical stage and is being shepherded under the FDA's Breakthrough Devices and TAP frameworks [PR Newswire] [PUBLIC]. Breakthrough status does not shorten the requirement for clinical evidence, but it does support more frequent FDA interaction during study design, which can compress the timeline between bench work and a pivotal trial. TAP enrollment, still a relatively new FDA program, adds structured engagement with payers, providers, and investors during product development, a feature that medical device founders have publicly cited as useful for de-risking reimbursement assumptions before a pivotal study locks in [PR Newswire] [PUBLIC].

Material details on the implant's polymer chemistry, fixation mechanism, manufacturing partners, and pre-clinical animal study results are not disclosed in the public sources reviewed, and the company has not published peer-reviewed data that the research engine surfaced. Investors evaluating the technology will need to request the pre-clinical data package, the FDA pre-submission correspondence, and the intellectual property file (presumably licensed from Georgia Tech) directly from the company.

Data Accuracy: YELLOW -- Product positioning confirmed by PR Newswire and Hypepotamus; technical specifics not publicly disclosed.

Market Research and Opportunity

PUBLIC

Meniscus injury is one of the most common orthopedic conditions in the developed world, and the standard of care has known long-term costs that the device industry has been trying to address for two decades. Meniscal tears are routinely cited as among the most frequent indications for arthroscopic knee surgery in the United States, and partial meniscectomy, while symptom-relieving in the short term, is associated with elevated risk of post-traumatic osteoarthritis and eventual total knee replacement. That clinical pathway is what creates the addressable opportunity for a durable meniscus replacement: not just the surgery itself, but the avoided downstream cost of arthroplasty in younger patients.

The research engine did not surface a named third-party TAM figure specific to meniscus replacement implants, so any sizing here would be inferred rather than cited. As an analogous reference, the broader knee reconstruction and orthopedic reconstructive device market is dominated by large public players including Stryker, Zimmer Biomet, and Smith & Nephew, whose knee franchises generate multi-billion dollar annual revenues, which is the commercial pool a successful meniscus-preserving device would address by deferring or reducing demand for arthroplasty (analogous market, public company disclosures).

Demand drivers that the cited research surfaces include a large and growing pool of younger, active patients who are poor candidates for total knee replacement, surgeon and payer interest in joint-preserving alternatives, and the FDA's explicit prioritization of devices that address serious conditions where existing alternatives are limited, which is the regulatory rationale Breakthrough Designation rests on [PR Newswire]. Adjacent and substitute markets include cartilage repair products, meniscal allograft transplantation, biologic injectables, and eventually partial or total knee arthroplasty itself; each represents either a competing therapy or a downstream market a successful preservation device would compress.

Market signal Detail Source
FDA Breakthrough Device Designation Granted for OrthoPreserve meniscus implant [PR Newswire]
FDA TAP enrollment Accepted into Total Product Life Cycle Advisory Program [PR Newswire]
Named competitors in segment Active Implants, Orteq Ltd, Stryker (adjacent) [CB Insights]

Analyst takeaway: the most defensible market claim today is regulatory rather than quantitative. OrthoPreserve has two FDA signals in hand that competitors in the same segment would have to match, and the strategic logic (defer arthroplasty in younger patients) aligns with where payers and large orthopedic incumbents have publicly said they want the field to move.

Data Accuracy: YELLOW -- Regulatory milestones confirmed by PR Newswire; market sizing inferred from public company disclosures and not from a named third-party report.

Competitive Landscape

MIXED

OrthoPreserve is positioned in a small but persistent category of meniscus replacement and meniscus-preserving implants, where the principal alternatives are either earlier-generation devices from focused competitors or the cartilage and reconstruction franchises of large orthopedic incumbents.

Company Positioning Stage / Funding Notable Differentiator Source
OrthoPreserve Synthetic meniscus implant for knee pain Pre-clinical; NIH SBIR + Activation Capital FDA Breakthrough Device Designation and TAP enrollment [PR Newswire] [PUBLIC]; [CB Insights] [PUBLIC]
Active Implants NUsurface meniscus implant Commercial outside U.S.; clinical in U.S. (reported) First-mover with extensive U.S. clinical trial history (reported) [CB Insights] [PUBLIC]
Orteq Ltd Actifit meniscal scaffold Commercial in select markets (reported) Biodegradable scaffold approach for partial meniscus loss (reported) [CB Insights] [PUBLIC]
Stryker Knee reconstruction and cartilage repair franchises Public (NYSE: SYK) Distribution scale and bundled hospital relationships [CB Insights] [PUBLIC]

The segment map breaks into three groups. Focused meniscus replacement programs (Active Implants, Orteq, OrthoPreserve) compete on whether a synthetic or scaffold device can deliver durable, load-bearing function in a real knee over many years, which is fundamentally a clinical-evidence contest. Adjacent biologic and cartilage-repair products compete for the same surgeon decision at the point of arthroscopy, but address slightly different lesions. Large reconstruction incumbents like Stryker do not compete head-to-head today but own the downstream arthroplasty market that any successful meniscus preservation device would partially cannibalize, which makes them the most natural strategic acquirers.

Where OrthoPreserve has a defensible edge today is regulatory positioning and university-anchored IP. Breakthrough Device Designation and TAP enrollment are not awarded broadly, and they materially change the cadence of FDA interaction during pivotal trial design [PR Newswire]. The Georgia Tech origin and ATDC support give the company a credible technical lineage and a low-cost operating base in Atlanta. That edge is perishable in two specific ways: a Breakthrough designation does not by itself establish clinical superiority, and competitors who already have years of human implant data carry an evidence advantage that takes time and capital to close.

Where OrthoPreserve is most exposed is on clinical history. Active Implants has reportedly been in U.S. clinical study for years, which means it could reach a U.S. approval decision earlier and define the reimbursement narrative for the entire category. Stryker, while not a direct competitor today, controls the surgeon and hospital channel that any meniscus replacement device ultimately needs to reach, and could choose to partner with whichever focused player produces the cleanest pivotal data.

The most plausible 18-month competitive scenario is one in which one of the focused meniscus players posts a positive interim clinical readout and triggers either a strategic investment or an acquisition conversation with a large reconstruction incumbent. Winner if X: OrthoPreserve secures a well-structured pivotal trial design under TAP and lines up named academic investigators, in which case its capital-efficient profile becomes attractive to a strategic. Loser if Y: a competitor such as Active Implants reaches a U.S. approval decision first and locks in the initial CPT and coverage framework, leaving later entrants to compete on incremental data.

Data Accuracy: YELLOW -- OrthoPreserve milestones confirmed by PR Newswire; competitor positioning drawn from CB Insights category data and public company information, with some details flagged as reported.

Opportunity

PUBLIC

If OrthoPreserve reaches the U.S. market with a meniscus implant supported by durable clinical data, the size of the prize is the share of the multi-billion dollar knee reconstruction economy that shifts upstream into preservation.

The headline opportunity. The single largest outcome OrthoPreserve could plausibly become is the default synthetic meniscus replacement in the United States for patients whose tissue cannot be repaired and who are too young for total knee arthroplasty. That is not an aspirational framing; it follows directly from the FDA's decision to grant Breakthrough Device Designation, which the agency reserves for devices addressing serious conditions where existing alternatives are limited [PR Newswire]. Combined with TAP enrollment, which structures payer and provider input during development, the regulatory pathway is unusually well scaffolded for a pre-clinical company [PR Newswire]. The cited evidence makes a meaningful U.S. franchise a reachable rather than speculative outcome, conditional on clinical execution.

Two or three growth scenarios.

Scenario What happens Catalyst Why it's plausible
Strategic acquisition by a knee reconstruction incumbent A large orthopedic player (e.g. a Stryker-class acquirer) buys OrthoPreserve to add a preservation device to its knee franchise Positive pivotal study readout under the TAP-aligned trial Large incumbents already operate adjacent cartilage and reconstruction lines and have a pattern of acquiring focused device companies after pivotal data [CB Insights]
Independent U.S. commercial launch OrthoPreserve raises a clinical-stage round, runs its pivotal trial, secures FDA approval, and launches with a focused U.S. surgeon-targeted commercial team FDA approval following a Breakthrough-designated pathway Breakthrough designation has been associated with more frequent FDA engagement and, in some categories, faster review timelines [PR Newswire]
Category standard for joint preservation The OrthoPreserve device becomes the reference implant cited in surgeon training and payer coverage decisions for synthetic meniscus replacement First or near-first U.S. approval combined with multi-year follow-up data The category currently lacks a broadly adopted U.S.-approved synthetic meniscus replacement, leaving room for whichever program produces the cleanest data to define the standard [CB Insights]

What compounding looks like. Medical device flywheels run on clinical evidence and surgeon adoption rather than software-style network effects. For OrthoPreserve, the compounding loop begins with a well-designed pivotal study supported by the TAP framework, which produces published data that drives surgeon training, which drives implant volume, which generates real-world evidence that supports broader payer coverage, which in turn funds the next indication or geographic expansion. The early evidence that this loop is starting is the FDA's willingness to grant both Breakthrough and TAP status, which signals that the agency sees the unmet need as serious enough to warrant priority engagement [PR Newswire].

The size of the win. A useful comparable is the broader knee reconstruction market dominated by Stryker, Zimmer Biomet, and Smith & Nephew, whose knee franchises generate multi-billion dollar annual revenues at the public-company level. A meniscus preservation device that meaningfully defers arthroplasty in younger patients addresses a slice of that downstream economy. If the strategic acquisition scenario plays out, comparable focused orthopedic device acquisitions have historically closed at meaningful multiples to invested capital, and a Breakthrough-designated, TAP-enrolled asset with a clean pivotal readout would be a scarce object in the orthopedic M&A market (scenario, not a forecast). If the independent commercial launch scenario plays out, the upside is a durable, surgeon-anchored franchise in a category with limited approved alternatives. Both outcomes are conditional on clinical data the company has not yet generated, which is why the next 18 months of trial design and capital formation are the period worth tracking most closely.

Data Accuracy: YELLOW -- Regulatory and competitor anchors confirmed by PR Newswire and CB Insights; financial outcomes presented explicitly as scenarios rather than forecasts.

Sources

PUBLIC

  1. [PR Newswire] OrthoPreserve Receives Both FDA Breakthrough Device Designation and Prestigious TAP Enrollment for Meniscus Implant | https://www.prnewswire.com/news-releases/orthopreserve-receives-both-fda-breakthrough-device-designation-and-prestigious-tap-enrollment-for-meniscus-implant-to-rework-knee-pain-treatment-302363541.html

  2. [Georgia Tech, July 2024] Tech Alum Launches Meniscus Implant Startup | https://news.gatech.edu/news/2024/07/11/tech-alum-launches-meniscus-implant-startup

  3. [Georgia Tech Research] Tech Alum Launches Meniscus Implant Startup | https://research.gatech.edu/tech-alum-launches-meniscus-implant-startup

  4. [CB Insights] OrthoPreserve - Products, Competitors, Financials, Employees, Headquarters Locations | https://www.cbinsights.com/company/orthopreserve

  5. [Hypepotamus] CEO Q&A: How A Graduate Thesis Turned Into MedTech Startup OrthoPreserve | https://hypepotamus.com/news/ceo-qa-how-a-graduate-thesis-turned-into-medtech-startup-orthopreserve/

  6. [Southeast Venture Showcase] OrthoPreserve, Inc. | https://southeastventureshowcase.com/teams/orthopreserve-inc

  7. [OrthoPreserve] Mission - OrthoPreserve: Meniscus Implant for Knee Pain Treatment | https://www.orthopreserve.com/mission

Articles about Ortho Preserve

View on Startuply.vc